Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism

Blood

Volumn 103, Issue 6, 2004, Pages 2157-2161

  Colucci, Mario ^a   Binetti, Bianca M ^b   Tripodi, Armando ^b   Chantarangkul, Veena ^b   Semeraro, Nicola ^b  

^a POLICLINICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; CARBOXYPEPTIDASE B; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; GENE MUTATION; HETEROZYGOTE; HUMAN; HYPERPROTHROMBINEMIA; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

EID: 1542283733     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2169     Document Type: Article

References (30)

1. Vicente V, Gonzales-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thrombosis. Haematologica. 1999;84:356-362.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
3. Kyrle PA, Mannhalter C, Beguin S, et al. Clinical studies and thrombin generation in patients homozygous and heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998;18:1287-1291.
4. Eikelboom JW, Ivey L, Ivey J, Baker RI. Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. Blood Coagul Fibrinolysis. 1999;10:1-5.
5. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol. 2000;20:2511-2518.
6. Lisman T, Leebek FWG, Mosnier LO, et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131-139.
7. Gils A, Alessi M-C, Brouwers E, et al. Development of a genotype 325-specific proCPU-TAFI ELISA. Arterioscler Thromb Vasc Biol. 2003;23:1122-1127.
8. Bertina RM, van der Marel-van Nieuwkoop W, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemost. 1979;42:1296-1305.
9. Lisman T, Leebek FWG, Meijer K, Van Der Meer J, Nieuwenhuis K, De Groot P. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology. 2002;35:616-621.
10. Sakharov D, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 1997;272:14477-14482.
11. Colucci M, Binetti BM, Branca MG, et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38:230-237.
12. Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFa generated by clot-bound and fluid phase thrombin. Thromb Haemost. 2002;88:282-287.
13. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem. 2002;277:1021-1030.
14. Bouma BN, Meijers JCM. Thrombin activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost. 2003;1:1566-1574.
15. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823.
16. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995;86:3035-3042.
17. Broze GJ Jr. Thrombin-dependent inhibition of fibrinolysis. Curr Opin Hematol. 1996;3:390-394.
18. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997;99:2323-2327.
19. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175-179.
20. Mosnier LO, Lisman T, van der Berg HM, Nieuwenhuis HK, Meijers JCM, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost. 2001;86:1035-1039.
21. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie Y-G. Combined carrier status of prothrombin 20210A and factor XIII-ALeu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood. 2003;101:3037-3041.
22. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood. 2003;101:3008-3013.
23. Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombosis by neutralization of factor XI. J Clin Invest. 1998;101:10-14.
24. Gresele P, Momi S, Berrettini M, Schwarz HP, Semeraro N, Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest. 1998;101:667-676.
25. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood. 1999;94:2735-2743.
26. Nagashima M, Werner M, Wang M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombosis model. Thromb Res. 2000;98:333-342.
27. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998;80:829-835.
28. Van Tilburg NH, Rosendaal FR, Betna RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859.
29. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696-701.
30. Leiden. J Biol Chem. 1996;271:22949-22952.